Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer Health Study Area: Breast Cancer For Caregivers For Caregivers For Clinicians Communities FAQs For Parents For Parents For Patients For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch. Health Study Area: NASH Instagram Created with sketchtool. For Clinicians

Inicie sesión o únase ahora para utilizar esta función

Not Yet Recruiting

A Study to Evaluate the Safety, Tolerability, and Drug Levels of BMS-986337 When Taken by Mouth by Healthy Participants - IM037-009

Actualizada: 11 septiembre, 2020   |   ClinicalTrials.gov

Imprimir Resumen

¿ESTÁ CONSIDERANDO PARTICIPAR EN ESTE ESTUDIO?
Imprima esta página y la guía del estudio para poder hablar mejor con su médico.
Use la guía de estudios para explorar el proceso de participación en un estudio clínico. Comprenda qué factores clave debe considerar antes de decidirse y piense preguntas para hacerle a su equipo de atención médica.

Detalles del estudio

  • Phase 1

    Fase

  • Géneros

  • 21-65

    Rango de edad

  • 1

    Ubicación (es)

  • Not Yet Recruiting

Opciones de tratamiento

Brazos del estudio
INTERVENCIÓN ASIGNADA
Experimental: Part A SAD Cohort A2
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part A SAD Cohort A3
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part A SAD Cohort A4
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part A SAD Cohort A5
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part A SAD Cohort A6
Biological: Famotidine Drug: BMS-986337
Experimental: Part A Single Ascending Dose (SAD) Cohort A1
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part B MAD Cohort B2
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part B MAD Cohort B3
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part B MAD Cohort B4
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part B Multiple Ascending Dose (MAD) Cohort B1
Drug: BMS-986337 Other: BMS-986337 Placebo
Experimental: Part C MAD in Japanese Healthy participants Cohort C1
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part C MAD in Japanese Healthy participants Cohort C2
Other: BMS-986337 Placebo Drug: BMS-986337
Experimental: Part C MAD in Japanese Healthy participants Cohort C3
Other: BMS-986337 Placebo Drug: BMS-986337

Criterios clave de elegibilidad

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: - No clinically significant deviation from normal in medical history, physical examination, electrocardiograms (ECGs), and clinical laboratory determinations - For Japanese cohorts in Part C, must be first-generation Japanese (born in Japan, not living outside of Japan for more than 10 years, and both parents are ethnically Japanese) - Body mass index (BMI) of 18.0 kg/m^2 to 30.0 kg/m^2, inclusive, at screening; BMI = weight (kg)/height (m)^2 - Women and men must agree to follow specific methods of contraception, if applicable Exclusion Criteria: - Women who are of childbearing potential - Women who are breastfeeding - Prior exposure to BMS-986278 - Positive nasopharyngeal reverse transcriptase polymerase chain reaction (RT-PCR) test for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on Day -2 Other protocol-defined inclusion/exclusion criteria apply

Recomendamos encarecidamente que se comunique con BMS para informar los efectos secundarios (eventos adversos)
Los efectos secundarios (eventos adversos) y otros eventos reportables se definen aquí
Informe de efectos secundarios (eventos adversos) o quejas sobre la calidad del producto: información médica

¿Tiene alguna pregunta? El soporte en vivo está disponible 24/7 - Llame 855-907-3286 o Envíenos un correo electrónico

¿Tiene alguna pregunta? El soporte en vivo está disponible 24/7 -
Llame 855-907-3286 o Envíenos un correo electrónico